secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001493152-24-008508
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics receives approval to transfer stock listing from Nasdaq Global Market to Capital Market
--------------------------------------------------------------------------------

- Received Nasdaq approval on Feb 29, 2024 to transfer listing from Global Market to Capital Market.
- Transfer effective as of open of business on March 1, 2024; ticker ZVSA unchanged.
- Cures prior deficiency in minimum Market Value of Publicly Held Shares (MVPHS) requirement.
- Company had 7,583,863 shares of common stock outstanding as of March 1, 2024.
- Nasdaq Capital Market has similar corporate governance requirements but different listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224008508/0001493152-24-008508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224008508/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer